000125848 001__ 125848
000125848 005__ 20240228143336.0
000125848 0247_ $$2doi$$a10.1007/s00259-015-3206-3
000125848 0247_ $$2pmid$$apmid:26508290
000125848 0247_ $$2ISSN$$a0340-6997
000125848 0247_ $$2ISSN$$a1432-105X
000125848 0247_ $$2ISSN$$a1619-7070
000125848 0247_ $$2ISSN$$a1619-7089
000125848 0247_ $$2altmetric$$aaltmetric:4700482
000125848 037__ $$aDKFZ-2017-01972
000125848 041__ $$aeng
000125848 082__ $$a610
000125848 1001_ $$0P:(DE-He78)c420f6efccb409e1a287be027501a74c$$aFreitag, Martin$$b0$$eFirst author$$udkfz
000125848 245__ $$aComparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.
000125848 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2016
000125848 3367_ $$2DRIVER$$aarticle
000125848 3367_ $$2DataCite$$aOutput Types/Journal article
000125848 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524733420_25151
000125848 3367_ $$2BibTeX$$aARTICLE
000125848 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125848 3367_ $$00$$2EndNote$$aJournal Article
000125848 520__ $$aTo evaluate the reproducibility of the combination of hybrid PET/MRI and the (68)Ga-PSMA-11 tracer in depicting lymph node (LN) and bone metastases of prostate cancer (PC) in comparison with that of PET/CT.A retrospective analysis of 26 patients who were subjected to (68)Ga-PSMA PET/CTlow-dose (1 h after injection) followed by PET/MRI (3 h after injection) was performed. MRI sequences included T1-w native, T1-w contrast-enhanced, T2-w fat-saturated and diffusion-weighted sequences (DWIb800). Discordant PET-positive and morphological findings were evaluated. Standardized uptake values (SUV) of PET-positive LNs and bone lesions were quantified and their morphological size and conspicuity determined.Comparing the PET components, the proportion of discordant PSMA-positive suspicious findings was very low (98.5 % of 64 LNs concordant, 100 % of 28 bone lesions concordant). Two PET-positive bone metastases could not be confirmed morphologically using CTlow-dose, but could be confirmed using MRI. In 12 of 20 patients, 47 PET-positive LNs (71.9 %) were smaller than 1 cm in short axis diameter. There were significant linear correlations between PET/MRI SUVs and PET/CT SUVs in the 64 LN metastases (p < 0.0001) and in the 28 osseous metastases (p < 0.0001) for SUVmean and SUVmax, respectively. The LN SUVs were significantly higher on PET/MRI than on PET/CT (p SUVmax < 0.0001; p SUVmean < 0.0001) but there was no significant difference between the bone lesion SUVs (p SUVmax = 0.495; p SUVmean = 0.381). Visibility of LNs was significantly higher on MRI using the T1-w contrast-enhanced fat-saturated sequence (p = 0.013), the T2-w fat-saturated sequence (p < 0.0001) and the DWI sequence (p < 0.0001) compared with CTlow-dose. For bone lesions, only the overall conspicuity was higher on MRI compared with CTlow-dose (p < 0.006).Nodal and osseous metastases of PC are accurately and reliably depicted by hybrid PET/MRI using (68)Ga-PSMA-11 with very low discordance compared with PET/CT including PET-positive LNs of normal size. The correlation between PET/MRI SUVs and PET/CT SUVs was linear in LN and bone metastases but was significantly lower in control (non-metastatic) tissue.
000125848 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000125848 588__ $$aDataset connected to CrossRef, PubMed,
000125848 650_7 $$2NLM Chemicals$$aGlu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))
000125848 650_7 $$2NLM Chemicals$$aOligopeptides
000125848 650_7 $$09G34HU7RV0$$2NLM Chemicals$$aEdetic Acid
000125848 7001_ $$0P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aRadtke, Jan Philipp$$b1$$udkfz
000125848 7001_ $$aHadaschik, Boris A$$b2
000125848 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b3$$udkfz
000125848 7001_ $$0P:(DE-He78)331382460d902d1341dc73db8b990f97$$aEder, Matthias$$b4$$udkfz
000125848 7001_ $$0P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aKopka, Klaus$$b5$$udkfz
000125848 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b6$$udkfz
000125848 7001_ $$0P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac$$aRöthke, Matthias$$b7$$udkfz
000125848 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b8$$udkfz
000125848 7001_ $$0P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aAfshar-Oromieh, Ali$$b9$$eLast author$$udkfz
000125848 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-015-3206-3$$gVol. 43, no. 1, p. 70 - 83$$n1$$p70 - 83$$tEuropean journal of nuclear medicine and molecular imaging$$v43$$x1619-7089$$y2016
000125848 909CO $$ooai:inrepo02.dkfz.de:125848$$pVDB
000125848 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c420f6efccb409e1a287be027501a74c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000125848 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000125848 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000125848 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)331382460d902d1341dc73db8b990f97$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000125848 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000125848 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000125848 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000125848 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000125848 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000125848 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000125848 9141_ $$y2016
000125848 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125848 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125848 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125848 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000125848 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000125848 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000125848 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125848 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000125848 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125848 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125848 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000125848 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000125848 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000125848 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000125848 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000125848 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x2
000125848 980__ $$ajournal
000125848 980__ $$aVDB
000125848 980__ $$aI:(DE-He78)E010-20160331
000125848 980__ $$aI:(DE-He78)C060-20160331
000125848 980__ $$aI:(DE-He78)E030-20160331
000125848 980__ $$aUNRESTRICTED